Uber Technologies Inc.’s scandal-plagued year apparently hasn’t deterred ridership, though the ride-hailing company is still reporting heavy financial losses.
NYS Entity Status
NYS Filing Date
JULY 26, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - NEXT RIDE MOTOR INC
AROUND THE WEB
- Uber Racks Up Rides, Losses Amid Setbacks
Wednesday Aug 23, 2017
- SUMMER FIRSTS | Brooklyn: Finding Alchemy and Art on a Coney Island Scary Ride
By FRANCINE PROSE - Wednesday Aug 2, 2017
For Francine Prose, an amusement-park trip as a young girl led to a ride on the Spook-a-Rama and later to a prized Diane Arbus photo of the same ride.
- In Pivotal Moment, Tesla Unveils Its First Mass-Market Sedan
By BILL VLASIC - Saturday Jul 29, 2017
Elon Musk, Tesla’s chief executive, delivered 30 cars to employees chosen to be the first owners. The electric-car maker faces a challenge in meeting the sizable demand.
- Tesla Yields Place Atop U.S. Automakers as Stock Slumps
By NEAL E. BOUDETTE - Thursday Jul 6, 2017
The electric-car maker’s shares are off sharply after a report of production trouble, giving General Motors back its No. 1 spot after less than three months.
- Uber and Yandex, a Russian Ride-Hailing Rival, Opt to Share the Road
By MIKE ISAAC - Thursday Jul 13, 2017
The competitors have decided to stop battling for market share and instead operate jointly in a handful of Eastern European countries.
- Cancer drug research moving fast in immunotherapy field
By Michelle Fay Cortez - Tuesday Sep 5, 2017
The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.